Molecule Details
InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N
Compound NameEvobrutinib
Canonical SMILESC=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)4
Pfam Stratification Homologous
Avg pChEMBL7.6
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB15170
Drug NameEvobrutinib
CAS Number1415823-73-2
Groups investigational
ATC Codes nan
DescriptionEvobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).

Cross-references: BindingDB: 291522 CHEMBL4072833 ChemSpider: 58827807 PDB: MZJ ZINC: ZINC000205623965
Target Activities (4)
Target Gene Organism Category Pfam pChEMBL Type Source
Q06187 BTK Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 7.8 IC50 ChEMBL;BindingDB
P42680 TEC Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 7.7 IC50 ChEMBL;BindingDB
P51813 BMX Homo sapiens Human PF00779 PF00169 PF07714 PF00017 7.5 IC50 ChEMBL;BindingDB
Q15303 ERBB4 Homo sapiens Human PF00757 PF14843 PF07714 PF01030 PF21314 7.4 IC50 ChEMBL;BindingDB
DrugBank Target Actions (1)
Target Gene Target Name Action Type
Q06187 BTK Tyrosine-protein kinase BTK inhibitor targets